Clinical Trials
2 trialsNCT03532217 2022-08-05
Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer
Washington University School of Medicine
Phase 1 Completed
NCT03343977 2018-07-17
Toxicity & Pharmacokinetics of 2 & 3-weekly Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
University of Kentucky
Phase 1/2 Withdrawn